The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
(Q45016242)
scientific article
scientific article
Language:
other details
| description | scientific article |
External Links
| (P356) |
10.1038/LEU.2008.235
|
| (P698) |
18769451
|
| (P6179) |
1037023799
|